1Gotto A, Pownall H. Lipid - Regulation Drugs and Low - Density Lipoprotein Aaph - eresis Gotto A, Pownall H, Eds. Manual of Lipid Disorders. 2eded. Lippincott Williams & Wilkins, 1999. 292 ～ 328 被引量：1
2Bakker- Arkema RG, Davidson MH, Coldstein RJ, et al. Efficacy and safety of a new HMG - GoAreductase inhibitor, atrovastatin, in patients with hypertrigl yceridemia JAMA, 1996,275 (2): 128 ～ 133 被引量：1
3Jones P, Kafonek S, Laurora I, et al. Comparative dose efficacy study of atrovastatin versus simvastatin, pravastatin, lovastatin, and fiuvastatin in patients with hypercholesterolemia (the CUPVES study). Am J Cardiol, 1998,81(5) :582 ～ 587 被引量：1
4Guan Y, Breyer MD. Peroxisome oroliferator - activated receptors (PPARs) :Novel theraputic targets in renal disease. Kidney Int,2001,60(1):14～30 被引量：1
5Taelsb, Dallongville J, Auwerx J,et al. Mechaniams of action of fibrate on lipid and lipoprotein metabolism. Circulation, 1998, 98 ( 19 ): 2088 ～ 2093 被引量：1
6Ruotolo G, Ericsson CG, Tettarmanti C, et al. Treatment effect on serumlipoprotine lipids, apolipoproteins and low density liporotine particle size and relationships of lipoprotine variables to progression of coronary artery disease in the Bezafibrate Cotonary Atherosclerosis Intervention Trial(BECAIT) [ J]. J Am Coll Cardiol, 1998,32:1648 被引量：1
7Morgan JM. Treamant and Effect of Niaspan, a Controlled - release Niacin,in Patients with Hypercholes terolemia is A Plcebo- controlled Trial.J Cardiovase Pharmacol Ther, 1996, (3): 195 ～ 202 被引量：1
10Texje R, Pedersen MD, Anders G, et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the 4s. Circulation, 1998,97(15): 1453 被引量：1
